Vanda Pharmaceuticals (VNDA) Cash from Investing Activities (2010 - 2026)

Vanda Pharmaceuticals has disclosed Cash from Investing Activities across 17 years of filings, most recently posting $20.2 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $20.2 million, down 53.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $71.2 million (up 59.3% YoY), and the FY2025 annual result was $94.9 million, up 644.23% from the prior year.
• Cash from Investing Activities came in at $20.2 million for Q1 2026 at Vanda Pharmaceuticals, down from $44.9 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $187.3 million in Q1 2023 to a low of -$190.9 million in Q2 2023.
• The 5-year median for Cash from Investing Activities is $10.9 million (2022), against an average of $8.0 million.
• Across the five-year window, Cash from Investing Activities surged 15204.23% in 2022 and tumbled 1208.21% in 2023, its largest moves.
• Vanda Pharmaceuticals' Cash from Investing Activities stood at $75.4 million in 2022, then slumped by 158.05% to -$43.8 million in 2023, then soared by 109.12% to $4.0 million in 2024, then jumped by 1023.62% to $44.9 million in 2025, then slumped by 54.9% to $20.2 million in 2026.
• The last three Cash from Investing Activities figures came in at $20.2 million (Q1 2026), $44.9 million (Q4 2025), and $21.4 million (Q3 2025), per Business Quant data.